keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis cardiovascular event

keyword
https://www.readbyqxmd.com/read/29149819/cardiovascular-risk-in-psoriasis-current-state-of-the-art
#1
Giuseppe Dattilo
Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of psoriatic arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients...
November 16, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29145701/tnf-antagonists-killing-two-birds-with-one-biologic-stone
#2
EDITORIAL
Joan M Bathon, Jon T Giles, Daniel H Solomon
Forty years have passed since it was first recognized that patients with autoimmune rheumatic disease have an increased risk of fatal and non-fatal cardiovascular (CV) events (1) Although initial reports focused on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), similar findings were verified subsequently in patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) and spondyloarthritis. An early feature of the atherosclerotic lesion is infiltration with inflammatory cells, particularly monocytes/macrophages, and the presence of these cells in mature plaque elevates the risk of plaque rupture and thrombosis (2)...
November 16, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29094341/safety-efficacy-and-drug-survival-of-biologics-and-biosimilars-for-moderate-to-severe-plaque-psoriasis
#3
A Egeberg, M B Ottosen, R Gniadecki, S Broesby-Olsen, T N Dam, L E Bryld, M K Rasmussen, L Skov
BACKGROUND: Real-life data on newer biologic and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy, and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics...
November 1, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29065479/psoriasis-and-cardiovascular-comorbidities-focusing-on-severe-vascular-events-cardiovascular-risk-factors-and-implications-for-treatment
#4
REVIEW
Stephen Chu-Sung Hu, Cheng-Che E Lan
Psoriasis is a common and chronic inflammatory disease of the skin. It may impair the physical and psychosocial function of patients and lead to decreased quality of life. Traditionally, psoriasis has been regarded as a disease affecting only the skin and joints. More recently, studies have shown that psoriasis is a systemic inflammatory disorder which can be associated with various comorbidities. In particular, psoriasis is associated with an increased risk of developing severe vascular events such as myocardial infarction and stroke...
October 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29055628/visceral-adiposity-in-psoriasis-is-associated-with-vascular-inflammation-by-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-beyond-cardiometabolic-disease-risk-factors-in-an-observational-cohort-study
#5
Joshua P Rivers, Tiffany M Powell-Wiley, Amit K Dey, Justin A Rodante, Jonathan H Chung, Aditya A Joshi, Balaji Natarajan, Aparna P Sajja, Abhishek Chaturvedi, Anshuma Rana, Charlotte L Harrington, Heather L Teague, Benjamin N Lockshin, Mark A Ahlman, Jianhua Yao, Martin P Playford, Joel M Gelfand, Nehal N Mehta
OBJECTIVES: We sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by (18)fluorodeoxyglucose ((18)FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND: PSO, a chronic inflammatory skin disease, is associated with VI by (18)FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation...
October 14, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29038899/the-use-of-primary-prevention-statin-therapy-in-those-predisposed-to-atherosclerosis
#6
REVIEW
Michael Garshick, James A Underberg
PURPOSE OF REVIEW: Many guidelines exist for the use of statins in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Few have focused on disease specific states that predispose to ASCVD. This review is intended to focus on the recommendations and evidence in inflammatory diseases that predispose to an increased risk of ASCVD beyond what conventional cardiac risk scores would predict. RECENT FINDINGS: Certain autoimmune inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), and psoriasis/psoriatic arthritis have all been shown to increase the risk of ASCVD...
October 17, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29036254/evaluation-of-risk-of-major-adverse-cardiovascular-events-with-biologic-therapy-in-patients-with-psoriasis
#7
Robert Bissonnette, Francisco Kerdel, Luigi Naldi, Kim Papp, Claudia Galindo, Wayne Langholff, K L Tang, Philippe Szapary, Steven Fakharzadeh, Bhaskar Srivastava, Kavitha Goyal, Alice B Gottlieb
BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Longitudinal Assessment Registry (PSOLAR) is an international psoriasis registry of patients eligible to receive biologic/systemic treatments prospectively. MACE is defined as myocardial infarction, stroke, or cardiovascular death. Biologic cohorts, including tumor necrosis factor-alpha (TNF-α) inhibitors (ie, adalimumab, etanercept, and infliximab) and ustekinumab, combined and by class, were compared with a topical/phototherapy cohort...
October 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28980716/metabolic-parameters-in-psoriatic-patients-treated-with-interleukin-12-23-blockade-ustekinumab
#8
Chau Yee Ng, I-Shiang Tzeng, Su-Hsun Liu, Ya-Ching Chang, Yu-Huei Huang
The associations between psoriasis, metabolic syndrome and cardiovascular events are increasingly recognized. Studies have shown decreased cardiovascular events with the treatment of methotrexate and anti-tumor necrosis factor, however, effects of interleukin (IL)-12/23 blockade remain debatable. Our study investigated the effect of IL-12/23 blockade on the metabolic parameters in patients with psoriasis. We performed a retrospective cohort study to assess 93 consecutive patients with moderate to severe plaque type psoriasis who received IL-12/23 blockade (ustekinumab) for 24 weeks between January 2012 and May 2016...
October 5, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28895664/severe-and-acute-complications-of-biologics-in-psoriasis
#9
Elias Oussedik, Nupur U Patel, Devin R Cash, Angela S Gupta, Steven R Feldman
Biologic therapies have revolutionized the approach to immune-mediated diseases such as psoriasis. Due to their favorable safety profiles and excellent efficacy, biologic agents are considered the gold standard for moderate-to-severe psoriasis. The aim of this paper is to saliently review the severe and acute complications of the Food and Drug Administration (FDA) approved biologic agents for psoriasis. Reviewed agents include tumor necrosis factor alpha inhibitors (etanercept, infliximab, and adalimumab), interleukin 12/23 inhibitors (ustekinumab), and interleukin 17 (IL-17) inhibitors (secukinumab and ixekizumab)...
December 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28894050/compounds-of-psoriasis-with-obesity-and-overweight
#10
Agnieszka Owczarczyk-Saczonek, Waldemar Placek
Many epidemiological studies have confirmed the relationship of obesity and psoriasis, and it is believed that obesity is an independent risk factor for its development and is associated with a worse prognosis. Furthermore, the reduction of body weight, using low-calorie diet combined with exercise, reduces the severity of psoriasis.Visceral adipose tissue is the largest endocrine organ, producing proinflammatory cytokines (TNF-α, IL-6, IL-17) and adipokines (adiponectin, omentin, chemerin). They participate in the development of dyslipidemia, insulin resistance, diabetes, and consequently of the cardiovascular diseases...
August 24, 2017: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/28855659/increased-risk-of-atrial-fibrillation-and-thromboembolism-in-patients-with-severe-psoriasis-a-nationwide-population-based-study
#11
Tae-Min Rhee, Ji Hyun Lee, Eue-Keun Choi, Kyung-Do Han, HyunJung Lee, Chan Soon Park, Doyeon Hwang, So-Ryoung Lee, Woo-Hyun Lim, Si-Hyuck Kang, Myung-Jin Cha, Youngjin Cho, Il-Young Oh, Seil Oh
Psoriasis increases the risk of atrial fibrillation (AF) and thromboembolic events (TE). There is limited information on the effect of psoriasis severity on AF and TE. In this study, psoriasis patients were enrolled from the Korean National Insurance Service-National Sample Cohort (2004-2008). Diagnosis and disease severity were determined from claims data. Newly diagnosed non-valvular AF and TE were identified during a 9.6-year follow-up. The effect of psoriasis severity on AF and TE was evaluated. We identified 13,385 psoriasis patients (1,947 with severe psoriasis)...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28844116/cardiometabolic-disorders-in-psoriatic-disease
#12
REVIEW
Curtis Sobchak, Lihi Eder
PURPOSE OF REVIEW: Patients with psoriasis and psoriatic arthritis, collectively termed psoriatic disease (PsD), are at an increased risk of developing cardiovascular diseases (CVD). The purpose if this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of CVD in psoriatic patients and approaches to improve the management of these comorbidities. RECENT FINDINGS: Studies have shown that CVD risk is independent of traditional cardiovascular risk factors and is related to the systemic inflammatory nature of PsD...
August 26, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28837372/update-upon-efficacy-and-safety-of-etanercept-for-the-treatment-of-spondyloarthritis-and-juvenile-idiopathic-arthritis
#13
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich, Francesco Puppo
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept...
August 24, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28826925/the-relationship-between-duration-of-psoriasis-vascular-inflammation-and-cardiovascular-events
#14
Alexander Egeberg, Lone Skov, Aditya A Joshi, Lotus Mallbris, Gunnar H Gislason, Jashin J Wu, Justin Rodante, Joseph B Lerman, Mark A Ahlman, Joel M Gelfand, Nehal N Mehta
BACKGROUND: Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized. OBJECTIVES: We utilized two resources to understand the effect of psoriasis duration on vascular disease and CV events: (1) a human imaging study and (2) a population-based study of CVD events. METHODS: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient)...
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28815476/long-term-safety-and-effectiveness-of-adalimumab-for-moderate-to-severe-psoriasis-results-from-7-year-interim-analysis-of-the-esprit-registry
#15
Alan Menter, Diamant Thaçi, Jashin J Wu, William Abramovits, Francisco Kerdel, Dilek Arikan, Dianlin Guo, Arijit Ganguli, Mareike Bereswill, Anne Camez, Wendell C Valdecantos
INTRODUCTION: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry. METHODS: All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed...
September 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28758265/risk-of-aortic-aneurysm-in-patients-with-psoriasis-a-retrospective-cohort-study
#16
LETTER
D J No, M Amin, L Duan, A Egeberg, O Ahlehoff, J J Wu
No abstract text is available yet for this article.
July 31, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28735613/does-treatment-of-psoriasis-reduce-cardiovascular-comorbidities
#17
REVIEW
Mark Lebwohl
Psoriasis has been associated with an increase in myocardial infarctions. Several registries have shown reductions in major adverse cardiovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosis factor-α antagonists. Many assume that the reduction in cardiovascular events can be attributed to the anti-inflammatory effect of tumor necrosis factor blockers, but a 52-week study conducted by Bissonnette and coworkers failed to show a reduction in cardiovascular inflammation in psoriasis patients treated with adalimumab...
August 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28670544/randomized-placebo-control-study-of-metformin-in-psoriasis-patients-with-metabolic-syndrome-systemic-treatment-cohort
#18
Surjit Singh, Anil Bhansali
BACKGROUND: Psoriasis has been found to be associated with obesity, metabolic syndrome (MS), diabetes, and cardiovascular risk factors. Metformin treatment showed improvement in cardiovascular risk factors and hyperinsulinemia. OBJECTIVE: To evaluate the efficacy and safety of metformin in psoriasis patients with MS. MATERIALS AND METHODS: This was a single-center, parallel-group, randomized, open-label study with blinded end point assessment of metformin (1000 mg once daily for 12 weeks; n = 20) and placebo (n = 18) in psoriasis patients with MS...
July 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28610662/clinical-diagnostic-and-therapeutic-implications-in-psoriasis-associated-with-cardiovascular-disease
#19
C Bonanad, E González-Parra, R Rivera, J M Carrascosa, E Daudén, A Olveira, R Botella-Estrada
In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of risk factors and metabolic syndrome, as well as an increased risk of major cardiovascular events such as myocardial infarction, cerebrovascular disease, and peripheral arterial disease...
November 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28601812/cardiovascular-and-type-2-diabetes-morbidity-and-all-cause-mortality-among-diverse-chronic-inflammatory-disorders
#20
Alex Dregan, Phil Chowienczyk, Mariam Molokhia
OBJECTIVES: The present study aimed to assess the relationship between inflammatory disorders with cardiometabolic diseases and mortality within a community-based population. METHODS: The UK Biobank data were used to conduct two investigations: a cross-sectional study to estimate cardiometabolic risk and a prospective cohort study to estimate mortality risk. Binary regression analyses were used to model the association between coronary heart disease, stroke, type 2 diabetes, venous thromboembolism and peripheral artery disease diagnoses with seven inflammatory disorders (eg, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, ankylosing spondylitis (AS), systemic vasculitis, Crohn's disease and ulcerative colitis (UC))...
June 10, 2017: Heart: Official Journal of the British Cardiac Society
keyword
keyword
114302
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"